Zenas BioPharma, Inc. (ZBIO)
ZBIO Stock Price Chart
Explore Zenas BioPharma, Inc. interactive price chart. Choose custom timeframes to analyze ZBIO price movements and trends.
ZBIO Company Profile
Discover essential business fundamentals and corporate details for Zenas BioPharma, Inc. (ZBIO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
13 Sept 2024
Employees
130.00
Website
https://zenasbio.comCEO
Leon Oliver Moulder Jr.
Description
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
ZBIO Financial Timeline
Browse a chronological timeline of Zenas BioPharma, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.89, while revenue estimate is $15.00m.
Earnings released on 13 May 2026
EPS came in at -$1.46 falling short of the estimated -$1.37 by -6.57%.
Earnings released on 16 Mar 2026
EPS came in at -$1.10 falling short of the estimated -$1.00 by -9.85%.
Earnings released on 12 Nov 2025
EPS came in at -$1.22 falling short of the estimated -$0.87 by -40.23%.
Earnings released on 12 Aug 2025
EPS came in at -$1.25 falling short of the estimated -$1.02 by -22.55%.
Earnings released on 15 May 2025
EPS came in at -$0.80 surpassing the estimated -$1.11 by +27.93%, while revenue for the quarter reached $10.00m , beating expectations by +700.00%.
Earnings released on 25 Mar 2025
EPS came in at -$3.99 falling short of the estimated -$0.92 by -333.70%, while revenue for the quarter reached $5.00m .
Earnings released on 12 Nov 2024
EPS came in at -$5.02 surpassing the estimated -$9.33 by +46.20%.
Earnings released on 30 Jun 2024
EPS came in at -$0.99 .
Earnings released on 31 Mar 2024
EPS came in at -$0.73 .
Earnings released on 31 Dec 2023
EPS came in at -$0.64 .
Earnings released on 30 Sept 2023
EPS came in at $0.85 , while revenue for the quarter reached $50.00m .
Earnings released on 30 Jun 2023
EPS came in at -$0.76 .
Earnings released on 31 Mar 2023
EPS came in at -$0.50 .
Earnings released on 31 Dec 2022
EPS came in at -$0.50 .
ZBIO Stock Performance
Access detailed ZBIO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
